Hikma Pharmaceuticals PLC
HKMPY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,127,000 | $2,875,000 | $2,517,000 | $2,553,000 |
| % Growth | 8.8% | 14.2% | -1.4% | – |
| Cost of Goods Sold | $1,712,000 | $1,468,000 | $1,279,000 | $1,252,000 |
| Gross Profit | $1,415,000 | $1,407,000 | $1,238,000 | $1,301,000 |
| % Margin | 45.3% | 48.9% | 49.2% | 51% |
| R&D Expenses | $141,000 | $149,000 | $144,000 | $143,000 |
| G&A Expenses | $568,000 | $638,000 | $509,000 | $488,000 |
| SG&A Expenses | $568,000 | $638,000 | $509,000 | $488,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $94,000 | $253,000 | $303,000 | $88,000 |
| Operating Expenses | $803,000 | $1,040,000 | $956,000 | $719,000 |
| Operating Income | $612,000 | $367,000 | $282,000 | $582,000 |
| % Margin | 19.6% | 12.8% | 11.2% | 22.8% |
| Other Income/Exp. Net | -$158,000 | -$86,000 | -$49,000 | -$39,000 |
| Pre-Tax Income | $454,000 | $281,000 | $233,000 | $543,000 |
| Tax Expense | $93,000 | $89,000 | $42,000 | $124,000 |
| Net Income | $359,000 | $190,000 | $188,000 | $421,000 |
| % Margin | 11.5% | 6.6% | 7.5% | 16.5% |
| EPS | 3.24 | 1.7 | 1.68 | 3.64 |
| % Growth | 90.6% | 1.2% | -53.8% | – |
| EPS Diluted | 3.22 | 1.72 | 1.68 | 3.62 |
| Weighted Avg Shares Out | 110,667 | 111,184 | 111,864 | 115,500 |
| Weighted Avg Shares Out Dil | 111,747 | 111,184 | 112,500 | 116,500 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,000 | $7,000 | $3,000 | $30,000 |
| Interest Expense | $88,000 | $87,000 | $70,000 | $69,000 |
| Depreciation & Amortization | $197,000 | $191,000 | $190,000 | $167,000 |
| EBITDA | $727,000 | $559,000 | $688,000 | $766,000 |
| % Margin | 23.2% | 19.4% | 27.3% | 30% |